Skip to main content
Erschienen in: Archives of Gynecology and Obstetrics 1/2013

01.01.2013 | Gynecologic Oncology

The diagnostic and prognostic value of serum YKL-40 in endometrial cancer

verfasst von: Jiang-tao Fan, Xiao-hui Si, Yan Liao, Ping Shen

Erschienen in: Archives of Gynecology and Obstetrics | Ausgabe 1/2013

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the diagnostic and prognostic value of serum YKL-40 in endometrial cancer (EC).

Methods

Serum YKL-40 levels were detected and compared in 34 of the 50 cases with EC before surgery, in 22 of the 34 with EC after surgery, in 30 cases with uterine myoma, and in 30 healthy women as normal controls. Receiver operating characteristics (ROC) curves were adopted for diagnosis and calculation of area under each ROC curve in EC. The progression-free survival (PFS) and overall survival (OS) between YKL-40 positive and negative patients were compared in the follow-up.

Results

The mean pre-operative serum YKL-40 values were significantly higher than that in the uterine myoma cases and in the healthy women (P = 0.000). The mean post-operative serum YKL-40 in the 22 EC cases was significantly lower than pre-operative serum YKL-40 levels in these cases (P = 0.000). There were critical differences between the area under ROC curve for YKL-40 and CA125 (P = 0.053). The PFS and OS for the YKL-40-positive patients were significantly shorter than those for the YKL-40-negative patients.

Conclusion

Preliminary investigations have shown that serum YKL-40 level may have a definite clinical value in the diagnosis and prognosis of EC.
Literatur
1.
Zurück zum Zitat Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300PubMedCrossRef Jemal A, Siegel R, Xu J et al (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277–300PubMedCrossRef
2.
Zurück zum Zitat Somoye G, Olaitan A, Mocroft A et al (2005) Age related trends in the incidence of endometrial cancer in south east England 1962–1997. J Obstet Gynaecol 25(1):35–38PubMedCrossRef Somoye G, Olaitan A, Mocroft A et al (2005) Age related trends in the incidence of endometrial cancer in south east England 1962–1997. J Obstet Gynaecol 25(1):35–38PubMedCrossRef
3.
Zurück zum Zitat Sonoda Y, Barakat RR (2006) Screening and the prevention of gynecologic cancer: endometrial cancer. Best Practice and Research. Clin Obstet Gynecol 20(2):363–377 Sonoda Y, Barakat RR (2006) Screening and the prevention of gynecologic cancer: endometrial cancer. Best Practice and Research. Clin Obstet Gynecol 20(2):363–377
4.
Zurück zum Zitat Hamilton CA, Cheung MK, Osann K et al (2006) Uterine papillary serous and clear cell carcinomas predict for for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94(5):642–646PubMed Hamilton CA, Cheung MK, Osann K et al (2006) Uterine papillary serous and clear cell carcinomas predict for for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94(5):642–646PubMed
5.
Zurück zum Zitat Dotters DJ (2000) Preoperative CA125 in endometrial cancer: is it useful? Am J Obstet Gynecol 182(6):1328–1334PubMedCrossRef Dotters DJ (2000) Preoperative CA125 in endometrial cancer: is it useful? Am J Obstet Gynecol 182(6):1328–1334PubMedCrossRef
6.
Zurück zum Zitat Hsieh CH, ChangChien CC, Lin H et al (2002) Can a preoperative CA125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol 86(1):28–33PubMedCrossRef Hsieh CH, ChangChien CC, Lin H et al (2002) Can a preoperative CA125 level be a criterion for full pelvic lymphadenectomy in surgical staging of endometrial cancer? Gynecol Oncol 86(1):28–33PubMedCrossRef
7.
Zurück zum Zitat Johansen JS, Jensen BV, Roslind A et al (2006) Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarker Prev 15(2):194–202CrossRef Johansen JS, Jensen BV, Roslind A et al (2006) Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarker Prev 15(2):194–202CrossRef
8.
Zurück zum Zitat Rehli M, Krause SW, Andreesen R (1997) Molecular characterization of gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43(2):221–225PubMedCrossRef Rehli M, Krause SW, Andreesen R (1997) Molecular characterization of gene for human cartilage gp-39 (CHI3L1), a member of the chitinase protein family and marker for late stages of macrophage differentiation. Genomics 43(2):221–225PubMedCrossRef
9.
Zurück zum Zitat Fusetti F, Pijning T, Kalk KH et al (2003) Crystal structure and carbohydrate-binding properties of human cartilage glycoprotein-39. J Biol Chem 278(39):37753–37760PubMedCrossRef Fusetti F, Pijning T, Kalk KH et al (2003) Crystal structure and carbohydrate-binding properties of human cartilage glycoprotein-39. J Biol Chem 278(39):37753–37760PubMedCrossRef
10.
Zurück zum Zitat Volck B, Price PA, Johansen JS et al (1998) YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110(4):351–360PubMed Volck B, Price PA, Johansen JS et al (1998) YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians 110(4):351–360PubMed
11.
Zurück zum Zitat Rehli M, Niller H–H, Ammon C et al (2003) Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 278(45):44058–44067PubMedCrossRef Rehli M, Niller H–H, Ammon C et al (2003) Transcriptional regulation of CHI3L1, a marker gene for late stages of macrophage differentiation. J Biol Chem 278(45):44058–44067PubMedCrossRef
12.
Zurück zum Zitat Nishikawa KC, Millis AJT (2003) Gp38 k (CHI3L1) is a novel adhesion and migration factor foe vascular cells. Exp Cell Res 287(1):79–87PubMedCrossRef Nishikawa KC, Millis AJT (2003) Gp38 k (CHI3L1) is a novel adhesion and migration factor foe vascular cells. Exp Cell Res 287(1):79–87PubMedCrossRef
13.
Zurück zum Zitat Bi J, Lau SH, Lv ZL et al (2009) Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol 40(12):1790–1797PubMedCrossRef Bi J, Lau SH, Lv ZL et al (2009) Overexpression of YKL-40 is an independent prognostic marker in gastric cancer. Hum Pathol 40(12):1790–1797PubMedCrossRef
14.
Zurück zum Zitat Hormigo A, Gu B, Karimi S et al (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12(19):5698–5704PubMedCrossRef Hormigo A, Gu B, Karimi S et al (2006) YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res 12(19):5698–5704PubMedCrossRef
15.
Zurück zum Zitat Yamac D, Ozturk B, Coskun U et al (2008) Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv Ther 25(8):801–809PubMedCrossRef Yamac D, Ozturk B, Coskun U et al (2008) Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer. Adv Ther 25(8):801–809PubMedCrossRef
16.
Zurück zum Zitat Thom I, Andritzky B, Schuch G et al (2010) Elevated pretreatment serum concentration of YKL-40-an independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 116(17):4114–4121PubMedCrossRef Thom I, Andritzky B, Schuch G et al (2010) Elevated pretreatment serum concentration of YKL-40-an independent prognostic biomarker for poor survival in patients with metastatic nonsmall cell lung cancer. Cancer 116(17):4114–4121PubMedCrossRef
17.
Zurück zum Zitat Høgdall EV, Ringsholt M, Høgdall CK et al (2009) YKL-40 tissue expression and plasma level in patients with ovarian cancer. BMC Cancer 9:8–18PubMedCrossRef Høgdall EV, Ringsholt M, Høgdall CK et al (2009) YKL-40 tissue expression and plasma level in patients with ovarian cancer. BMC Cancer 9:8–18PubMedCrossRef
18.
Zurück zum Zitat Johansen JS, Williamson MK, Rice JS et al (1992) Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 7(5):501–512PubMedCrossRef Johansen JS, Williamson MK, Rice JS et al (1992) Identification of proteins secreted by human osteoblastic cells in culture. J Bone Miner Res 7(5):501–512PubMedCrossRef
19.
Zurück zum Zitat Shao R, Hamel K, Petersen L et al (2009) YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28(50):4456–4468PubMedCrossRef Shao R, Hamel K, Petersen L et al (2009) YKL-40, a secreted glycoprotein, promotes tumor angiogenesis. Oncogene 28(50):4456–4468PubMedCrossRef
20.
Zurück zum Zitat Dupont J, Tanwar MK, Thaler HT et al (2004) Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 22(16):3330–3339PubMedCrossRef Dupont J, Tanwar MK, Thaler HT et al (2004) Early detection and prognosis of ovarian cancer using serum YKL-40. J Clin Oncol 22(16):3330–3339PubMedCrossRef
21.
Zurück zum Zitat Diefenbach CS, Shah Z, Iasonos A et al (2007) Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol 104(2):435–442PubMedCrossRef Diefenbach CS, Shah Z, Iasonos A et al (2007) Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer. Gynecol Oncol 104(2):435–442PubMedCrossRef
22.
Zurück zum Zitat Høgdall EVS, Johansen JS, Kjaer SK et al (2003) High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep 10(5):1535–1538PubMed Høgdall EVS, Johansen JS, Kjaer SK et al (2003) High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep 10(5):1535–1538PubMed
23.
Zurück zum Zitat Saidi A, Javerzat S, Bellahcène A et al (2008) Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer 122(10):2187–2198PubMedCrossRef Saidi A, Javerzat S, Bellahcène A et al (2008) Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer 122(10):2187–2198PubMedCrossRef
Metadaten
Titel
The diagnostic and prognostic value of serum YKL-40 in endometrial cancer
verfasst von
Jiang-tao Fan
Xiao-hui Si
Yan Liao
Ping Shen
Publikationsdatum
01.01.2013
Verlag
Springer-Verlag
Erschienen in
Archives of Gynecology and Obstetrics / Ausgabe 1/2013
Print ISSN: 0932-0067
Elektronische ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-012-2546-5

Weitere Artikel der Ausgabe 1/2013

Archives of Gynecology and Obstetrics 1/2013 Zur Ausgabe

Acknowledgement to Referees

Reviewers 2012

Hirsutismus bei PCOS: Laser- und Lichttherapien helfen

26.04.2024 Hirsutismus Nachrichten

Laser- und Lichtbehandlungen können bei Frauen mit polyzystischem Ovarialsyndrom (PCOS) den übermäßigen Haarwuchs verringern und das Wohlbefinden verbessern – bei alleiniger Anwendung oder in Kombination mit Medikamenten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

Bislang gibt es kein Medikament zur Prävention von Wochenbettdepressionen. Das Injektionsanästhetikum Esketamin könnte womöglich diese Lücke füllen.

Bei RSV-Impfung vor 60. Lebensjahr über Off-Label-Gebrauch aufklären!

22.04.2024 DGIM 2024 Kongressbericht

Durch die Häufung nach der COVID-19-Pandemie sind Infektionen mit dem Respiratorischen Synzytial-Virus (RSV) in den Fokus gerückt. Fachgesellschaften empfehlen eine Impfung inzwischen nicht nur für Säuglinge und Kleinkinder.

Update Gynäkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.